These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27101805)

  • 1. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.
    Bai WJ; Li HJ; Jin JJ; Xu WP; Sebastian S; Wang XF
    Asian J Androl; 2017; 19(4):500-504. PubMed ID: 27101805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
    Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
    Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
    Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
    J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
    Li HJ; Bai WJ; Dai YT; Xu WP; Wang CN; Li HZ
    Asian J Androl; 2016; 18(5):773-9. PubMed ID: 26459780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
    Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
    J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
    Eardley I; Mirone V; Montorsi F; Ralph D; Kell P; Warner MR; Zhao Y; Beardsworth A
    BJU Int; 2005 Dec; 96(9):1323-32. PubMed ID: 16287454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
    Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
    Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction.
    Rosen R; Broderick G; Shabsigh R; Swindle R; Lockhart D; Cameron A
    J Sex Med; 2005 Jul; 2(4):461-8. PubMed ID: 16422840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
    Ströberg P; Murphy A; Costigan T
    Clin Ther; 2003 Nov; 25(11):2724-37. PubMed ID: 14693300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
    Ahn TY; Lee SW; Kim SW; Yang DY; Park NC; Min KS; Park K; Paick JS; Dyachkova Y; Dwight T; Lee MS
    Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study.
    Hatzimouratidis K; Buvat J; Büttner H; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    Int J Impot Res; 2014; 26(6):223-9. PubMed ID: 24784894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy.
    Furtado TP; Miranda EP; Deveci S; Jenkins L; Narus J; Nelson C; Mulhall JP
    J Sex Med; 2023 Dec; 21(1):29-32. PubMed ID: 37973393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction.
    von Büren M; Rodler S; Wiesenhütter I; Schröder F; Buchner A; Stief C; Gratzke C; Wülfing C; von Büren J
    Eur Urol Focus; 2022 May; 8(3):794-802. PubMed ID: 34006491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
    Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
    J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
    Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
    J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term tadalafil once daily in Chinese men with erectile dysfunction: a 2-year final analysis of a post-marketing, multicenter, randomized, open-label trial.
    Jiang H; Zhao LM; Yan S; Liu JH; Zhu ZH; Luo JD; Dai YT; Li FB; Lin HC; Zhang ZC
    Asian J Androl; 2024 May; 26(3):282-287. PubMed ID: 38284776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.